Roche has had overwhelming success with PD-L1 inhibitor Tecentriq (atezolizumab) as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) – in just a few years, the drug has managed to pass the USD 1bn dollar annual revenue threshold, earning it the blockbuster title.
Since then, Roche has tried the substance in other indications, one of which seemingly panning out now. In a phase III study where Tecentriq was administered subcutaneously (as an injection under the skin) to treat NSCLC, the candidate met its endpoint, and the safety profile of the new version matches the old, the firm has announced in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Principal Laboratory Technologist Medicinal Chemistry 
Quality coordinator for Aseptic Production, ALK 
Antibody Engineering Scientist 
Clinical Project/Trial Manager, Synklino 
Clinical Trial Manager - Black Swans Exist 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Sales Director, Nordic Hospital Solutions, at Mediq Denmark 
GMP Compliance Consultant for Eltronic in Ballerup 
Lead Auditor – Senior Quality Assurance Specialist 
Director Regulatory Affairs 
Scientist Radiochemistry 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Clinical Biometrics Oversight Lead